Decreased 5-HT1A receptor binding in amygdala of schizophrenia

被引:85
|
作者
Yasuno, F
Suhara, T
Ichimiya, T
Takano, A
Ando, T
Okubo, Y
机构
[1] Natl Inst Radiol Sci, Brain Imaging Project, Inage Ku, Chiba 2638555, Japan
[2] Nippon Med Coll, Dept Psychiat, Tokyo 113, Japan
关键词
5-HT1A; schizophrenia; amygdala; anxiety; depression; negative symptoms;
D O I
10.1016/j.biopsych.2003.11.016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: On the basis of postmortem data and the pharmacological action of atypical antipsychotics, serotonin-1A receptors are of interest in the study of the pathophysiology of schizophrenia. To investigate serotonin-1A receptors in schizophrenia and their relation to symptoms.. we measured the availability of serotonin-1A receptors in patients with schizophrenia using positron emission tomography, with [carbonyl-C-11]WAY-100635. Methods: Serotonin-1A receptor binding of 11 patients with schizophrenia (8 drug-naive and 3 drug-free) was compared with, that of 22 age-matched and gender-matched healthy control subjects. Symptoms were assessed using the Positive and Negative Syndrome Scale. Serotonin-1A receptor binding in selected regions of interest was quantified by binding potential obtained by the reference tissue method. Results: The regional binding potential value was lower in the amygdala by about 19% in patients with, schizophrenia than in normal controls. A significant negative correlation was observed between binding potential in the amygdala and the negative and depression/anxiety Symptom scores on the five-symptom subscale of the Positive and Negative Syndrome Scale. Conclusions: Decreased serotonin-1A receptor binding in the amygdala may underlie the affective components included in the symptoms of negative and depression/anxiety in schizophrenia.
引用
收藏
页码:439 / 444
页数:6
相关论文
共 50 条
  • [31] A functional genetic variation of the 5-HT transporter affects 5-HT1A receptor binding in humans
    Murthy, NY
    David, S
    Rabiner, EA
    Johnstone, E
    Jacob, R
    Walton, R
    Grasby, PM
    JOURNAL OF PSYCHOPHARMACOLOGY, 2004, 18 (03) : A68 - A68
  • [32] Involvement of the 5-HT1A receptor in the anti-immobility effects of fluvoxamine in the forced swimming test and mouse strain differences in 5-HT1A receptor binding
    Sugimoto, Yumi
    Furutani, Sachiko
    Kajiwara, Yoshinobu
    Hirano, Kazufumi
    Yamada, Shizuo
    Tagawa, Noriko
    Kobayashi, Yoshiharu
    Hotta, Yoshihiro
    Yamada, Jun
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 629 (1-3) : 53 - 57
  • [33] Development of 5-HT1A receptor antagonists
    Routledge, C
    BEHAVIOURAL BRAIN RESEARCH, 1996, 73 (1-2) : 153 - 156
  • [34] LABELING OF THE 5-HT1A RECEPTOR SUBTYPE
    SHIH, JC
    ASARCH, KB
    RANSOM, R
    PSYCHOPHARMACOLOGY BULLETIN, 1986, 22 (03) : 818 - 824
  • [35] Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia
    Hurlemann, R
    Boy, C
    Meyer, PT
    Scherk, H
    Wagner, M
    Herzog, H
    Coenen, HH
    Vogeley, K
    Falkai, P
    Zilles, K
    Maier, W
    Bauer, A
    ANATOMY AND EMBRYOLOGY, 2005, 210 (5-6): : 519 - 523
  • [36] Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia
    René Hurlemann
    Christian Boy
    Philipp T. Meyer
    Harald Scherk
    Michael Wagner
    Hans Herzog
    Heinz H. Coenen
    Kai Vogeley
    Peter Falkai
    Karl Zilles
    Wolfgang Maier
    Andreas Bauer
    Anatomy and Embryology, 2005, 210 : 519 - 523
  • [37] Recent 5-HT1A receptor agonists
    Gurwitz, D
    DRUG DISCOVERY TODAY, 1999, 4 (03) : 142 - 143
  • [38] The 5-HT1A receptor: Signaling to behavior
    Albert, Paul R.
    Vahid-Ansari, Faranak
    BIOCHIMIE, 2019, 161 : 34 - 45
  • [39] EFFECTS OF NOVEL 5-HT1A RECEPTOR ANTAGONISTS ON MEASURES OF POSTSYNAPTIC 5-HT1A RECEPTOR ACTIVATION IN-VIVO
    THIELEN, RJ
    FRAZER, A
    LIFE SCIENCES, 1995, 56 (07) : PL163 - PL168
  • [40] STRUCTURAL DETERMINANTS OF 5-HT1A VERSUS 5-HT1D RECEPTOR-BINDING SITE SELECTIVITY
    HARRINGTON, MA
    SLEIGHT, AJ
    PITHA, J
    PEROUTKA, SJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 194 (01) : 83 - 90